Literature DB >> 19463302

Randomized clinical trials and observational studies: guidelines for assessing respective strengths and limitations.

Edward L Hannan1.   

Abstract

The 2 primary types of studies that are used to test new drugs or procedures or compare competing drugs or types of procedures are randomized clinical trials (RCTs) and observational studies (OS). Although it would appear that RCTs always trump OS because they eliminate selection bias, there are many possible limitations to both types of studies, and these limitations must be carefully assessed when comparing the results of RCTs and OS. This state-of-the art review describes these limitations and discusses how to assess the validity of RCTs and OS that yield different conclusions regarding the relative merit of competing treatments/interventions.

Mesh:

Year:  2008        PMID: 19463302     DOI: 10.1016/j.jcin.2008.01.008

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  78 in total

1.  Serum 25-hydroxyvitamin D, vitamin D binding protein and risk of colorectal cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.

Authors:  Stephanie J Weinstein; Mark P Purdue; Stephanie A Smith-Warner; Alison M Mondul; Amanda Black; Jiyoung Ahn; Wen-Yi Huang; Ronald L Horst; William Kopp; Helen Rager; Regina G Ziegler; Demetrius Albanes
Journal:  Int J Cancer       Date:  2014-09-02       Impact factor: 7.396

Review 2.  Strategies for postmarketing surveillance of drugs and devices in patients with ESRD undergoing dialysis.

Authors:  Moshe Vardi; Robert W Yeh; Charles A Herzog; Wolfgang C Winkelmayer; Soko Setoguchi; David M Charytan
Journal:  Clin J Am Soc Nephrol       Date:  2013-08-22       Impact factor: 8.237

3.  From controlled trial to community adoption: the multisite translational community trial.

Authors:  David L Katz; Mary Murimi; Anjelica Gonzalez; Valentine Njike; Lawrence W Green
Journal:  Am J Public Health       Date:  2011-06-16       Impact factor: 9.308

Review 4.  New directions in clinical outcomes assessment : VIth International Symposium on Interventional Electrophysiology in the Management of Cardiac Arrhythmias.

Authors:  Sana M Al-Khatib
Journal:  J Interv Card Electrophysiol       Date:  2011-08-20       Impact factor: 1.900

5.  Head tremor at disease onset: an ataxic phenotype of cervical dystonia.

Authors:  Aristide Merola; Alok K Dwivedi; Aasef G Shaikh; Tamour Khan Tareen; Gustavo A Da Prat; Marcelo A Kauffman; Jennie Hampf; Abhimanyu Mahajan; Luca Marsili; Joseph Jankovic; Cynthia L Comella; Brian D Berman; Joel S Perlmutter; Hyder A Jinnah; Alberto J Espay
Journal:  J Neurol       Date:  2019-04-26       Impact factor: 4.849

6.  Fine-tuning treatment for patients with ST-elevation myocardial infarction.

Authors:  Feng Qian; Edward L Hannan
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

7.  Real-World Evidence: Promise and Peril For Medical Product Evaluation.

Authors:  Sanket S Dhruva; Joseph S Ross; Nihar R Desai
Journal:  P T       Date:  2018-08

8.  Not-in-trial simulation I: Bridging cardiovascular risk from clinical trials to real-life conditions.

Authors:  Anne S Y Chain; Jeanne P Dieleman; Charlotte van Noord; Albert Hofman; Bruno H Ch Stricker; Meindert Danhof; Miriam C J M Sturkenboom; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2013-12       Impact factor: 4.335

9.  Survival effect of first- and second-line treatments for patients with primary glioblastoma: a cohort study from a prospective registry, 1997-2010.

Authors:  Francesca Nava; Irene Tramacere; Andrea Fittipaldo; Maria Grazia Bruzzone; Francesco Dimeco; Laura Fariselli; Gaetano Finocchiaro; Bianca Pollo; Andrea Salmaggi; Antonio Silvani; Mariangela Farinotti; Graziella Filippini
Journal:  Neuro Oncol       Date:  2014-01-23       Impact factor: 12.300

Review 10.  Osteoporosis therapies: evidence from health-care databases and observational population studies.

Authors:  Stuart L Silverman
Journal:  Calcif Tissue Int       Date:  2010-08-20       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.